Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: Does the order of sequencing matter?

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1908-1913

  Calvani, N ^a   Morelli, F ^b   Leo, S ^c   Orlando, L ^a   Lombardi, L ^b   Gnoni, A ^c   Cinefra, M ^a   Maiello, E ^b   Lorusso, V ^c   Cinieri, S ^d  

^a Sen Antonio Perrino Hospital   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c VITO FAZZI HOSPITAL   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Angiogenic inhibitors; Renal cell cancer; Sorafenib tosylate; Sunitinib malate; Targeted molecular therapy

Indexed keywords

EVEROLIMUS; SORAFENIB; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CLINICAL ARTICLE; DRUG DOSE SEQUENCE; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HISTOLOGY; HUMAN; INCIDENCE; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SKIN TOXICITY; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRROLES; RETROSPECTIVE STUDIES;

EID: 84872811400     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0048-0     Document Type: Article

References (13)

1. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408-17.
2. Ainsworth NL, Lee JS, Eisen T. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2009;9:1793-805.
3. Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-109.
4. Mendel DB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327-37.
5. Di Lorenzo G. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol. 2009;27:4469-74.
6. Kontovinis L, et al. Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. Med Oncol. 2011. doi:10.1007/s12032-010-9815-6.
7. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009;115:61-7.
8. Porta C, et al. Retrospective analysis of the sequential use of sorafenib and sunitinib in patients with advanced renal cell carcinoma. European association of urology congress. 2009. Abstract 252.
9. Sablin MP, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182:29-34.
10. Choueiri T, et al. Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC). Ann Oncol. 2008; Suppl 8: Abstract p 593.
11. Huang D, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010;70:1063-71.
12. Hammers HJ, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther. 2010;9:1525-35.
13. Tang TC, et al. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia. 2010;12:928-40.